These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 21951562)
1. mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients. Santarpia M; Magri I; Sanchez-Ronco M; Costa C; Molina-Vila MA; Gimenez-Capitan A; Bertran-Alamillo J; Mayo C; Benlloch S; Viteri S; Gasco A; Mederos N; Carcereny E; Taron M; Rosell R J Transl Med; 2011 Sep; 9():163. PubMed ID: 21951562 [TBL] [Abstract][Full Text] [Related]
2. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations. Karachaliou N; Costa C; Gimenez-Capitan A; Molina-Vila MA; Bertran-Alamillo J; Mayo C; Massuti B; Majem M; Carcereny E; Moran T; Sanchez JJ; Viteri S; Gasco A; Wannesson L; Souglakos J; Jimeno J; Rosell R; J Thorac Oncol; 2013 Mar; 8(3):295-300. PubMed ID: 23407556 [TBL] [Abstract][Full Text] [Related]
3. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. Rosell R; Perez-Roca L; Sanchez JJ; Cobo M; Moran T; Chaib I; Provencio M; Domine M; Sala MA; Jimenez U; Diz P; Barneto I; Macias JA; de Las Peñas R; Catot S; Isla D; Sanchez JM; Ibeas R; Lopez-Vivanco G; Oramas J; Mendez P; Reguart N; Blanco R; Taron M PLoS One; 2009; 4(5):e5133. PubMed ID: 19415121 [TBL] [Abstract][Full Text] [Related]
4. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Rosell R; Molina MA; Costa C; Simonetti S; Gimenez-Capitan A; Bertran-Alamillo J; Mayo C; Moran T; Mendez P; Cardenal F; Isla D; Provencio M; Cobo M; Insa A; Garcia-Campelo R; Reguart N; Majem M; Viteri S; Carcereny E; Porta R; Massuti B; Queralt C; de Aguirre I; Sanchez JM; Sanchez-Ronco M; Mate JL; Ariza A; Benlloch S; Sanchez JJ; Bivona TG; Sawyers CL; Taron M Clin Cancer Res; 2011 Mar; 17(5):1160-8. PubMed ID: 21233402 [TBL] [Abstract][Full Text] [Related]
5. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance. Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788 [TBL] [Abstract][Full Text] [Related]
6. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. Papadaki C; Sfakianaki M; Ioannidis G; Lagoudaki E; Trypaki M; Tryfonidis K; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J J Thorac Oncol; 2012 Apr; 7(4):663-71. PubMed ID: 22425915 [TBL] [Abstract][Full Text] [Related]
7. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Bartolucci R; Wei J; Sanchez JJ; Perez-Roca L; Chaib I; Puma F; Farabi R; Mendez P; Roila F; Okamoto T; Taron M; Rosell R Clin Lung Cancer; 2009 Jan; 10(1):47-52. PubMed ID: 19289372 [TBL] [Abstract][Full Text] [Related]
8. Over-expression of AEG-1 significantly associates with tumour aggressiveness and poor prognosis in human non-small cell lung cancer. Song L; Li W; Zhang H; Liao W; Dai T; Yu C; Ding X; Zhang L; Li J J Pathol; 2009 Nov; 219(3):317-26. PubMed ID: 19644957 [TBL] [Abstract][Full Text] [Related]
9. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Bivona TG; Hieronymus H; Parker J; Chang K; Taron M; Rosell R; Moonsamy P; Dahlman K; Miller VA; Costa C; Hannon G; Sawyers CL Nature; 2011 Mar; 471(7339):523-6. PubMed ID: 21430781 [TBL] [Abstract][Full Text] [Related]
10. AEG-1 mRNA expression in non-small cell lung cancer is associated with increased tumor angiogenesis. Ma Z; Chen Y; Dong S; Xu X; Liu J; Song P; Yu C; Dai L Pathol Res Pract; 2017 Oct; 213(10):1257-1263. PubMed ID: 28941723 [TBL] [Abstract][Full Text] [Related]
11. Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. Inno A; Di Noia V; Martini M; D'Argento E; Di Salvatore M; Arena V; Schinzari G; Orlandi A; Larocca LM; Cassano A; Barone C Pathol Oncol Res; 2019 Apr; 25(2):513-520. PubMed ID: 29557085 [TBL] [Abstract][Full Text] [Related]
12. Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS). Kotoula V; Krikelis D; Karavasilis V; Koletsa T; Eleftheraki AG; Televantou D; Christodoulou C; Dimoudis S; Korantzis I; Pectasides D; Syrigos KN; Kosmidis PA; Fountzilas G BMC Cancer; 2012 Aug; 12():342. PubMed ID: 22866924 [TBL] [Abstract][Full Text] [Related]
13. Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. Liang H; Zhang J; Shao C; Zhao L; Xu W; Sutherland LC; Wang K J Exp Clin Cancer Res; 2012 Apr; 31(1):36. PubMed ID: 22537942 [TBL] [Abstract][Full Text] [Related]
14. Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC. Zhou H; Dai Y; Zhu L; Wang C; Fei X; Pan Q; Chen J; Shi X; Yang Y; Tao X; Shi P J Int Med Res; 2016 Feb; 44(1):89-98. PubMed ID: 26740498 [TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells. Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110 [TBL] [Abstract][Full Text] [Related]
16. Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells. Lin Y; Higashisaka K; Shintani T; Maki A; Hanamuro S; Haga Y; Maeda S; Tsujino H; Nagano K; Fujio Y; Tsutsumi Y Sci Rep; 2020 Mar; 10(1):4748. PubMed ID: 32179851 [TBL] [Abstract][Full Text] [Related]
17. Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide. Karachaliou N; Papadaki C; Lagoudaki E; Trypaki M; Sfakianaki M; Koutsopoulos A; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J PLoS One; 2013; 8(9):e74611. PubMed ID: 24058603 [TBL] [Abstract][Full Text] [Related]
18. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC; Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794 [TBL] [Abstract][Full Text] [Related]
19. [Association between the epidermal growth receptor status and the efficacy of first-line chemotherapy in patients with advanced non-small cell lung cancer]. Qin N; Zhang Q; Wang J; Zhang H; Gu Y; Yang X; Li X; Lv J; Wu Y; Nong J; Zhang X; Zhang S Zhongguo Fei Ai Za Zhi; 2015 Mar; 18(3):131-7. PubMed ID: 25800568 [TBL] [Abstract][Full Text] [Related]
20. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Ren S; Chen X; Kuang P; Zheng L; Su C; Li J; Li B; Wang Y; Liu L; Hu Q; Zhang J; Tang L; Li X; Zhou C; Schmid-Bindert G Cancer; 2012 Nov; 118(22):5588-94. PubMed ID: 22569898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]